INIFY LABORATORIES AB

F:WY60 Germany Diagnostics & Research
Market Cap
$24.30 Million
€23.67 Million EUR
Market Cap Rank
#46751 Global
#7789 in Germany
Share Price
€0.30
Change (1 day)
+0.00%
52-Week Range
€0.16 - €0.60
All Time High
€1.04
About

INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.

INIFY LABORATORIES AB (WY60) - Net Assets

Latest net assets as of : €- EUR

Based on the latest financial reports, INIFY LABORATORIES AB (WY60) has net assets worth €- EUR as of .

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets €-
% of Total Assets 0%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility N/A

INIFY LABORATORIES AB - Net Assets Trend (None–None)

This chart illustrates how INIFY LABORATORIES AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for INIFY LABORATORIES AB (None–None)

The table below shows the annual net assets of INIFY LABORATORIES AB from None to None.

Year Net Assets Change
No yearly data available.

Equity Component Analysis

This analysis shows how different components contribute to INIFY LABORATORIES AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • No equity composition insights available.

INIFY LABORATORIES AB Competitors by Market Cap

The table below lists competitors of INIFY LABORATORIES AB ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in INIFY LABORATORIES AB's equity between the two most recent reporting periods.

Insufficient data available to analyze equity growth attribution.

Book Value vs Market Value Analysis

This analysis compares INIFY LABORATORIES AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Insufficient data available to analyze book value vs market value.

Capital Efficiency Dashboard

This dashboard shows how efficiently INIFY LABORATORIES AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Insufficient data available to analyze capital efficiency metrics.

Industry Comparison

This section compares INIFY LABORATORIES AB's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $10,792,710,184
  • Average return on equity (ROE) among peers: -33.38%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
INIFY LABORATORIES AB (WY60) €- N/A N/A $2.92K
Spermosens AB (publ) (9R5) $23.64 Million -27.17% 0.09x $517.28K
BML Inc (BMZ) $81.13 Billion 8.19% 0.43x $462.01 Million
Genomic Vision Société Anonyme (G09) $3.07 Million -162.85% 1.21x $711.54K
ICON Public Limited Company (IJF) $1.85 Billion 17.96% 0.86x $6.58 Billion
Adicon Holdings Limited (K0U) $1.77 Billion 2.65% 1.64x $138.53 Million
WuXi XDC Cayman Inc. (L74) $1.48 Billion 10.52% 0.69x $2.05 Billion
NanoRepro AG (NN6) $57.61 Million 51.59% 0.37x $17.02 Million
PERRIGO (PGO) $24.67 Million -167.93% 0.99x $6.37K